Partnering opportunity

Early treatment of epilepsy in newborn offered by a French clinical research team


An innovative newborn-suitable galenic form has been set up for a vitamin-sensitive epilepsy drug. It has been designed and proved to be efficient by a French clinical research lab. The Technology Transfer Office (TTO) acting on behalf the clinical research team, is looking for pharmaceutical companies interested by a technical cooperation agreement or a licensing agreement.

Partner sought

Requested partners are companies operating in pharmaceutics or drug forms, that may be interested in : - a licencing agreement as the Technology Transfer Office (TTO) is ready to negotiate directly the patents rights so the partner can drive further clinical development of this new galenic solution for epilepsies in paediatrics, - a technical cooperation agreement based on the innovative galenic solution, in order to target other usecases or medical indications.


A French clinical research team has developed an innovative treatment for paediatric epileptic seizures coming from a vitamin-sensitive effect. This research team is represented by a Technology Transfer Office (TTO) which is responsible for protecting and leveraging the intellectual property. It aims to create the best conditions to bring to market innovative products and services directly from hospital care and clinical research. Market challenges : The highest epilepsy prevalence has been shown to occur during the neonatal period. About 1 per cent of live births have concerns with the incidence of epilepsies. Recovery ratio is limited under 50% using current treatment. This represents about 3 to 4 thousands of newborns per year. There is a need for another treatment leading to better results. In addition, it should be suitable for newborn and children. State of the art : The current treatment for paediatric epilepsies is phenobarbital administration. Unfortunately, the response of such a treatment is only about 50%. Focusing on non-responding clinical cases, it has been shown that it should be explained by a vitamin-sensitive epilepsy. On one hand, pyridoxine-dependent epilepsy comes from a lack of B6 vitamin. Another vitamin-dependent disease is the deficit in pyridoxamin 5-phosphate oxidase. This deficit comes from a lack of pyridoxal 5 phosphate (P5P), which is the active form of B6 vitamin. Unfortunately, there is no suitable galenic formulation which allows to administrate P5P in newborns. Moreover, diagnosis of vitamin-sensitive epilepsy can only be performed 2 weeks to 1 month after stating that phenobarbital is not relevant. Proposed technology : In order to optimize the treatment of both above-mentioned vitamin-sensitive epilepsies, a specific galenic formulation has been developed which allows the early administration of P5P in newborns who don't respond to phenobarbital drug. The developed formulation is an effervescent solution which allows a complete solubilization of P5P. Moreover, the resulting colourless aspect of the solution and the possibility of any aroma addition allows its use in paediatrics. The TTO acting on behalf the clinical research team, is looking after companies operating in pharmaceutics for paediatrics. Expected outcomes are either a technical cooperation agreement or a licensing agreement for futher clinical development. Keywords : pediatrics, neurology, reformulation, neonatal epilepsy, galenic.

Advantages and innovations

A new galenic formulation of Pyridoxal 5 Phosphate (P5P) has been set up by a French clinical research team. The formulation is an alternative treatment of epilepsy in newborns not-responding to phenobarbital, before and after confirmation of vitamin-dependent diagnosis. The advantages of this innovative formulation are : - fast and complete solubilization of P5P: about 4 times faster than with the current formulation with bicarbonate, - easy, newborn and child-suitable drug and dosage form, which ensures oral absorption of the right dose and its reproducibility, - gain in the nursing time : about 2 min are saved before each oral administration as compared to the current formulation.

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company